🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public.

At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground therapists, and in one-on-one conversations between medical professionals who understood its potential but could not openly have such discussions for fear of stigma or discreditation. During this time, ATMA’s co-founder David Harder was involved in leading discussion groups that resulted in increased underground support; however, when the book was released, interest in psychedelic-assisted therapy models exponentially multiplied.

The movement continued to pick up steam in 2020 as investors, corporate interest, and many Cannabis company executives realized the financial potential of this up-and-coming industry.

So, the question we ask ourselves now is whether this book (and the Netflix series of the same title) positively impacted this movement, or did it bring about unsustainable momentum? Has the hype of this multi-million dollar frenzy of investors and business-people looking for the ‘next big thing’ actually resulted in the loss of deep healing that comes from effective and respectful therapeutic protocols.

We personally believe there have been both positive and negative outcomes as a result of this movement. How to Change Your Mind has increased public awareness of this psychedelic-assisted therapy, thus introducing people to medicines that they would not have had the opportunity to engage with otherwise. To negate that is to ignore thousands of personal stories of mental health, personal development, and spiritual growth. It is like a giant spotlight has brought the truth of these medicines to the masses. People who were doubtful or even distrustful of these medicines are now willing to discuss how this movement could be a benefit to society, including those in more religious circles.

However, the compromise is that this new “industry” could lead to a repeat of the War on Drugs that occurred in the 1960’s and 1970’s.

We have begun to see the revival of anti-psychedelic initiatives targeting this movement. Podcasts and various voices are taking extremist and uninformed views that these medicines have no place in medicinal or psychological treatment.

Moving forward, we believe this movement requires growth and it must embrace the traditional uses of these medicines. The psychedelic models of financial monopolies, massive stock gains, trademarks on medicines that have been around for millennia, and companies seeking excessive profits need to be re-evaluated and their place in this movement reconsidered; otherwise, the progress that has been made thus far is futile. If the corporate elements of this movement are not re-examined, there is the potential it could return to an underground fringe movement.

A new treatment paradigm is warranted for psychedelics in which a more holistic approach is embraced. While How to Change Your Mind offers a brilliant overview of the events of the last several decades, and while Michael Pollan has given us a gift by introducing people to these medicines, those in the medical and psychological fields are not yet ready for the massive change that is coming. Psychedelics should not be treated like other pharmaceuticals, and it is imperative that psychologists and other medical professionals understand the unique nature of psychedelics; if treated like a conventional drug, there is the potential for grave outcomes to occur. Without the support of therapists, counsellors, and community, psychedelics should not be used. The in-and-out clinics where patients are administered ketamine or psilocybin as a one-off treatment does not reflect the message Michael Pollan has laid out.

Psychedelics can change your mind; as a result, they carry the potential to change your life.

But the Psychedelic “Renaissance” also has the potential to do a lot of damage.

Therapists looking to conduct psychedelic-assisted therapy must learn the best practices for these medicines in order for this therapy to be efficacious. This is why ATMA has become acutely focused on training therapists via heart-centered instructors and experts who understand the depth of these medicines.

How to Change Your Mind is worth watching, and if you have a passion for helping others navigate their way through mental health struggles, and experience personal development and spiritual awakening, this Netflix series is informative.

Lastly, before you engage in any psychedelic medicine work, please take the time to become fully trained and to understand how powerful these medicines can be when they are used in a proper manner.

Thank you

The ATMA Team

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

This trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner   The Role of Psychedelics in Therapeutic Breakthroughs One of the main goals of psychotherapy is to guide patients toward therapeuticbreakthroughs – defined as a significant, sometimes sudden, step forward or important realization. Oftentimes, in therapy, breakthroughs come after long, unproductive plateaus. Such realizations must come from

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Scroll to Top